Structure-activity relationship study of THZ531 derivatives enables the discovery of BSJ-01-175 as a dual CDK12/13 covalent inhibitor with efficacy in Ewing sarcoma.
European journal of medicinal chemistry
View this publicationEuropean journal of medicinal chemistry
View this publicationNature chemical biology
View this publicationNature chemical biology
View this publicationScience (New York, N.Y.)
View this publicationThe Journal of biological chemistry
View this publicationThe Journal of allergy and clinical immunology
View this publicationGenes & development
View this publicationImmunity
View this publicationNature chemical biology
View this publicationFEBS letters
View this publication